Thermo Fisher extends recent gains, shares track a strong week in the S&P 500

Thermo Fisher shares add to their recent advance on the NYSE, with supportive analyst ratings and sector momentum underpinning the stock’s move this week.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:47.

Thermo Fisher Scientific (US8835561023) is having a solid trading week on the NYSE, with the shares adding to recent gains and sentiment supported by analyst coverage and sector peers in the S&P 500 research tools space. MarketBeat highlights a positive tone around AI-linked products and growth targets for Thermo Fisher this week.

What the recent move shows

Thermo Fisher shares closed at 506.19 US dollars on the NYSE on June 25, 2026, up 2.84 percent for the session according to MarketBeat data. MarketBeat’s trading summary for TMO cites extended-hours pricing at around 511.58 dollars. The stock thus trades comfortably above the 500 dollar mark, which has acted as a psychological reference level for many large-cap US healthcare names.

TradingKey puts the closing price at 505.92 dollars for June 25, a similar level, and reports a daily move of roughly 2.79 percent and a market capitalization of about 188 billion dollars for Thermo Fisher. TradingKey’s overview page lists TMO with a trailing P/E ratio near 27.8 and sector-comparable valuation metrics. The company sits firmly in the large-cap bracket within the S&P 500 healthcare and life-science tools segment, alongside peers such as Danaher and Agilent Technologies.

Analyst stance and sector context

Analyst sentiment towards Thermo Fisher remains constructive. TradingKey aggregates an overall Buy rating on TMO and cites a consensus price target of around 605.94 dollars, implying a sizeable upside versus the current share price. The same source notes earnings per share of 17.78 on a trailing twelve-month basis. While individual house calls differ, the aggregated Buy stance contrasts with more mixed views in parts of the broader healthcare space.

MarketBeat’s commentary points to a combination of AI-related product momentum, management confidence in medium-term growth targets and supportive analyst coverage as drivers behind the recent share move for Thermo Fisher. In its review of Q1 earnings and sector peers, MarketBeat notes Thermo Fisher trading favourably versus other research tools and consumables stocks. Against a backdrop of steady demand for diagnostics, bioprocessing and analytical instruments, the stock’s performance this week fits a broader pattern of resilient life-science tools names within the S&P 500.

The business behind the stock

Thermo Fisher generates revenue by supplying instruments, consumables, software and services for laboratories and production environments across pharmaceuticals, biotechnology, diagnostics, academia and industrial markets. A central product family is its Applied Biosystems genetic analysis and sequencing platforms, which enable high-throughput DNA and RNA analysis for research and clinical applications. The company’s portfolio overview highlights brands such as Applied Biosystems, Invitrogen, Gibco and Ion Torrent within its life-science offering. These products sit alongside chromatography systems, mass spectrometers and laboratory equipment in an integrated toolkit for customers.

Where the shares trade today

Thermo Fisher Scientific shares (US8835561023) most recently traded around 506 dollars on the NYSE, with the June 25, 2026 close reported at 506.19 dollars and intraday indications near that level on June 26, 2026 in US dollars. MarketBeat’s quote page shows TMO at 506.19 dollars at the June 25 close.

Key data on the Thermo Fisher shares

• Company: Thermo Fisher Scientific Inc.
• ISIN: US8835561023
• WKN: 857209
• Ticker: TMO
• Trading venue: NYSE
• Price (as of 2026-06-26, 11:30): 506.19 USD
• Market cap: 188.01 billion USD (as of 2026-06-25)
• Sector / industry: Health Care / Life Science Tools & Services
• Index membership: S&P 500
• Next earnings date: not officially scheduled

Disclaimer: This article provides factual information on Thermo Fisher Scientific shares and does not contain investment advice, recommendations or personal financial guidance. All data are based on sources cited in the text and may change over time.